An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Carolina Ayelen IsnardiEmilce Edith SchneebergerJennifer L KreimerPaula Carolina LunaCristina EcheverríaKaren RobertsMaría Celina de la VegaBelen Maria VirasoroMargarita LandiRosana Maris QuintanaMaria Eugenia D'Angelo ExeniNora KoganIngrid PetkovicDora PereiraMaria de Los Ángeles CorreaMarcos David ZelayaYohana Soledad TisseraMaría Soledad Gálvez ElkinCecilia Nora PisoniCarla AlonsoAdriana Karina CogoMicaela Ana CosattiLucila GarcíaCinthya RetamozoMaría de Los Ángeles SeverinaRomina Estefania NietoMarcos RosemffetEduardo MussanoAna BertoliVerónica G SavioVanesa Laura CosentinoGuillermo J Pons-EstelPublished in: Clinical rheumatology (2022)
This study has been registered in ClinicalTrials.gov under the number: NCT04845997. Key Points • This study shows real-world data about efficacy and safety of SARS-CoV-2 vaccination in patients with rheumatic and immune-mediated inflammatory diseases. Interestingly, different types of vaccines were used including vector-based, mRNA, and inactivated vaccines, and mixed regimens were enabled. • A quarter of the patients presented an adverse event. The incidence of adverse events was significantly higher in those receiving mRAN-1273 and ChAdOx1 nCoV-19. • In this cohort, 5.1% presented SARS-CoV-2 infection after vaccination, in most cases mild.